Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)

August 21, 2025 4:09 AM EDT Send to a Friend
Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $135.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login